NAMENDA XR® Safety Profile
NAMENDA XR side effects and pharmacokinetic drug interactions
Adverse reactions observed with a frequency of ≥2% and occurring at a rate greater than placebo1
NAMENDA XR 28mg+AChEI
Infections and infestations
Musculoskeletal and connective tissue disorders
Renal and urinary disorders
- Discontinuation due to adverse reactions was 10% for the NAMENDA XR 28 mg+AChEI treatment group and 6.3%
for the placebo+AChEI treatment group. The most common adverse reaction that led to treatment discontinuation in this study
was dizziness, at a rate of 1.5% in the NAMENDA XR-treated group1
- No drug-drug interaction studies have been conducted with NAMENDA XR, specifically1
- No pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes are expected1
- The combined use of NAMENDA XR with other NMDA* antagonists (amantadine, ketamine, or
dextromethorphan) has not been systematically evaluated and such use should be approached with caution1
- Please see
full Prescribing Information
for complete details on pharmacokinetic drug interactions
Important Safety Information
- NAMENDA XR is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any
excipients used in the formulation.
Warnings and Precautions
- NAMENDA XR should be used with caution under conditions that raise urine pH (including alterations by diet,
drugs and the clinical state of the patient). Alkaline urine conditions may decrease the urinary elimination
of memantine, resulting in increased plasma levels and a possible increase in adverse effects.
- NAMENDA XR has not been systematically evaluated in patients with a seizure disorder.
Review efficacy in global function with NAMENDA XR 28 mg
Review efficacy in cognition with NAMENDA XR 28 mg
Learn about once-daily dosing with NAMENDA XR
NAMENDA XR (memantine HCl) extended-release Prescribing Information. Cincinnati, OH: Forest Pharmaceuticals, Inc.; 2014.